Aims: 2-(4-methyl-thiazol-5-yl) ethyl nitrate maleate (NMZM), a derivative of clomethiazole (CMZ), had been investigated for the treatment of Alzheimer's disease (AD).
| INTRODUC TI ON
GABA A receptor agonists are used to protect neuronal injury and ameliorate or reverse age-related cognitive deficits and are suggested as a new therapeutic strategy recently. 1, 2 In recent decades, it has been proposed that imbalance between excitatory and inhibitory neurotransmission systems might be a major cause of neurodegenerative disease. Therapeutic strategies aim to regulate excitatory and/or inhibitory neurotransmission and thereby to reestablish the balance between both systems has been demonstrated to improve AD symptoms. 3, 4 Glutamate excitotoxicity is one of the most extensively explored mechanisms of neuron loss or cognitive deficit and plays an important role in AD. Currently, one of FDA-approved pharmacological options for treatment of severe AD is NMDA antagonist memantine. It might prevent excitotoxicity by acting as a non-competitive antagonist for NMDA receptors activated by glutamate in vivo. 5 On the other hand, enhancement of inhibitory neurotransmission by GABA A receptor agonists seems to be a new approach for treating AD. Several previous studies have indicated that selective GABA A receptor agonists are capable of protecting neurons from
Aβ-induced neurotoxicity in various brain regions in rodents. 6, 7 Since neuroprotective effects of GABA modulators could be blocked by GABA A receptor antagonists, revealing that these neuroprotective effects were mediated by GABA A receptor activation or positive modulation 8 may provide a new strategy for AD treatment.
2-(4-methyl-thiazol-5-yl) ethyl nitrate (NMZ) is one of the de-
rivatives of chlormethiazole (CMZ), which showed neuroprotective activity in rodent models of cerebral ischemia 9 and in non-human primates after focal cerebral ischemia 10 ; however, the clinical trial for stroke was halted in phase III due to the failure of attaining the primary end point of improvement in the general population. 11, 12 Previous studies revealed that NMZ has neuroprotective effects on Aβ, glutamate, or oxygen-glucose deprivation (OGD)-induced neuron injury in vitro, which could be antagonized by GABA A receptor antagonist bicuculline, 13 an allosteric inhibitor of channel opening of the GABA A receptor. This result indicated that the neuroprotective effect of NMZ was mediated by the GABA A receptor. In vivo, NMZ has been shown to reverse the cognitive impairment induced by many chemical lesions 14 and to improve the learning and memory in rats with cognitive deficits in the cholinergic systems of the basal forebrain 15 and in APP/PS1 mice. 13 NMZ-treated 3 × Tg mice exhibited long-term potentiation (LTP) improvement via NO/cGMP, cognitive deficits reversing. 16 NMZ belongs to a series of NO-releasing hybrid agents and it is believed to be a novel therapeutic compound to treat Alzheimer's disease (AD). Though NO/sGC/cGMP/ CREB pathway is expected to be one of the primary mechanisms for its cognitive-enabling, learning and memory improving, and neuroprotective effects, 17 GABA A receptors may also be involved in the neuroprotective action of NMZ as described above.
NMZM ( Figure 1 ) is a maleate salt of NMZ. Recently, NMZM was synthesized to improve its drugability by improving its solubility and absorption. We supposed that NMZM might also have the ability to play its neuroprotective effect by acting on the GABA A receptor. However, the electrophysiological mechanisms of NMZ/ NMZM to improve the capability of learning and memory through GABA A receptors remain to be elucidated. In addition, the binding site of NMZM to act (direct or indirect) on GABA A receptors is also needed to be clarified. In the present study, we used scopol- receptors. Therefore, the role of the three main binding sites in regulating GABA A receptor-mediated ion channels and the interaction between the agonists/antagonists with NMZM were studied. The modulation of NMZM on activity of GABA A was also investigated. 
| MATERIAL S AND ME THODS

| Animals
| Drugs and reagents
| LTP recordings in vivo
Long-term potentiation recording was conducted as previously described with slight modification. 18 The rats were anesthetized and 
| Isolation and culture of primary hippocampal neurons
Primary cultures of hippocampal neurons were prepared from postnatal rat brains as described with slight modification. 19 Briefly, After 4-hours culture for adherence, culture medium was placed by the final culture medium (neurobasal medium with additions of B27 supplement, GlutaMAX supplement, and penicillin/streptomycin).
Cytosine arabinoside was added to the medium at the final concentration of 10 μmol/L for another 24 hours after 48 hours.
| Electrophysiological procedures
Cover slips were placed in a recording chamber on a Nikon TE2000-U inverted microscope and superfused continuously with an external solution at a rate of 1 mL/min at room temperature (23-25°C). The 
| Data analysis
The drug-elicited current amplitude was measured as the GABA A receptor response. The potentiation effect was determined by normalizing the GABA A receptor response in the presence of drugs to the GABA A receptor response in the absence of drugs. Normalization was calculated by the following equation: % potentiation = (peak current in the presence of drugs/peak current in the absence of drugs) × 100. Data are expressed as mean ± SEM. Concentration-response/potentiation data were fitted to a logistic equation (Origin pro7.5). EC 50 is the concentration of drug inducing a half-maximal response/potentiation unless otherwise specified; statistical analysis was performed using Student's t test.
| RE SULTS
| NMZM enhanced LTP in scopolamine rat model
Long-term potentiation (LTP) recording is a widely documented method for investigating the synaptic basis of learning and memory and it is induced by high frequency stimuli (HFS, described before). NMZM were given ip 40 minutes before HFS. NMZM had no significant effect on the LTP of normal control rats (1 mg/ kg: 188% ± 14% vs control group: 189% ± 21%, P > 0.05, n = 4; 3 mg/kg: 207% ± 21% vs control group: 189% ± 21%, P > 0.05, n = 4; Figure 2A ,B). Scopolamine-mediated suppression of LTP was significantly alleviated by NMZM 1 mg/kg and 3 mg/kg (183% ± 10% vs scop. group 153% ± 6%, P < 0.05, and 211% ± 14% vs scop. group 153% ± 6%, P < 0.01, respectively). These results indicated that NMZM had protective effects against scopolamine-induced damage of LTP ( Figure 2C ,D).
| Activation of GABA A receptor by NMZM in hippocampal neurons
GABA at concentrations ranging from 1 to 100 μmol/L was applied to hippocampal neurons; the inward chloride currents were measured F I G U R E 2 Effects of NMZM on the suppression of LTP induced by scopolamine (1 mg/kg, scop.) in the dentate gyrus of rats. A and B, After baseline recording for 15 min, rats were injected intraperitoneally (ip) with NMZM (1, 3 mg/kg) or vehicle. A series of high frequency stimulation (HFS) was given 40 min later. NMZM had no significant effect on the induction of LTP (1 mg/kg: 188% ± 14% vs control group 189% ± 21%, P > 0.05, n = 4; 3 mg/kg: 207% ± 21% vs control group 189% ± 21%, P > 0.05, n = 4). C and D, After baseline recording for 15 min, rats were injected intraperitoneally (ip) with NMZM (1, 3 mg/kg) or vehicle followed by injection of scopolamine (1 mg/kg) or vehicle after 10 min; the control group was given vehicle intraperitoneally only. A series of high frequency stimulation (HFS) was given 30 min later. Scopolamine-mediated suppression of LTP was significantly alleviated by NMZM (1 mg/kg: 183% ± 10% vs scop. group 153% ± 6%, P < 0.05, n = 7. 3 mg/kg: 211% ± 14% vs scop. group 153% ± 6%, P < 0.01, n = 6.). The difference of PS amplitude at 55-60 min between groups was detected by one-way ANOVA, # P < 0.05 vs control group, * P < 0.05 vs scop. group 
| NMZM enhanced the currents activated by
GABA in hippocampal neurons
To observe the action of NMZM in modulating GABA A receptor- 
| Flumazenil, a diazepam binding site antagonist, affected NMZM-potentiated GABA A currents
The above study confirmed that the GABA A -mediated current was potentiated by NMZM. However, it remains to be studied if a classic antagonist of GABA A receptor inhibits the effects of NMZM.
Flumazenil (flu) is a well-known antagonist of diazepam (DZP) which
is one of the classical agents of benzodiazepines and it has a specific binding site on the GABA A receptor. Flumazenil 10 μmol/L inhibited F I G U R E 4 NMZM positively modulated GABA A receptormediated current in hippocampal neurons. A, Representative traces of the responses to the application of 3 μmol/L GABA in the absence or presence of NMZM 300 and 1000 μmol/L. The holding potential was −70 mV. B, GABA A receptor-mediated current amplitude in the presence of NMZM (300 and 1000 μmol/L; n = 4-8). C, GABA-evoked current potentiation by NMZM was normalized to the corresponding concentration of GABA-evoked response. GABA-evoked current potentiation by NMZM showed that low concentration (1 μmol/L in hollow circle from 6 to 8 neurons and 3 μmol/L in solid circle from 5 to 7 neurons) GABAevoked current potentiation by NMZM was more significant than high concentration (10 μmol/L in hollow triangle from four neurons and 30 μmol/L in solid triangle from 4 to 6 neurons) GABA-evoked current potentiation by NMZM using t test analysis. D, Doseresponse curve for 3 μmol/L GABA-evoked current potentiation by NMZM. Data normalized to the 3 μmol/L GABA response. The EC 50 for the enhancing effect of NMZM on 3 μmol/L GABA-evoked current is determined to be 465 μmol/L. Data were obtained from 5 to 9 neurons diazepam (100 nmol/L)-potentiated GABA A currents (3 μmol/L GABA-evoked current, Figure 5A ,B), but it had no effect on NMZM (500 μmol/L)-potentiated GABA A current. These results suggested that the binding site of NMZM on GABA receptor was not the same as the binding site of benzodiazepines. Therefore, the binding site of NMZM on GABA A receptor needs to be further studied. 
| Etomidate (etomidate site)
Since NMZM did not act through the same binding site as diazepam 
| D ISCUSS I ON
Since glutamate-induced excitotoxicity in AD is well acknowledged, GABA A receptors' dysfunction is also shown in AD; activating or potentiating GABA A receptors seems to be more and more by regulating excitatory and/or inhibitory neurotransmission balance in neurodegenerative diseases, which acts as the GABA A receptor positive allosteric modulator. [30] [31] [32] As one of the CMZ derivatives, NMZ also exhibited neuroprotective effect, 33 and it was reported to modify the symptoms and condition of AD in several animal models. 16 In the present study, we demonstrated that NMZM, the deriva- Several studies had also revealed the neuroprotective effects of etomidate in different animal models: for example, in experimental spinal cord injury rats 36 or in ischemia-reperfusion model. 37, 38 However, these studies did not indicate that the neuroprotective effects were mediated by the GABA A receptor and the relevant ion channel currents, but focused on other research areas, such as antioxidation and so on. Accordingly, positive allosteric modulators which bind to the etomidate binding site may entrust GABA A receptor the ability of neuroprotection. Therefore, it is suggested that etomidate binding sites might be used as a new drug target for the treatment of AD via neuroprotective action.
The GABA A receptors are made up of subunits which form a receptor complex. Humans have 19 receptor subunits including α (1-6), β (1-3), and γ (1-3) . The most common complex that includes around 40% of the GABA A receptors is the α1β2γ2 combination. 39, 40 Barbiturates bind at a β-subunit that is distinct from the benzodiazepine binding site. 41 Etomidate binds to the β-subunit. 42 Figure 9 illustrated the structure of the GABA A receptor and its associated binding sites, which bind to ligand or allosteric modulators such as benzodiazepines, barbiturates, and etomidate.
In summary, NMZM could improve LTP deficits induced by scopolamine, which demonstrated that NMZM had a capability of improving learning and memory. NMZM potentiated GABA A receptor as a positive allosteric modulator, but it is not a direct activator. The binding site of NMZM on GABA A receptor may be the same as etomidate. Our results indicated that the modulation of GABA A receptor is an important mechanism of NMZM in neuroprotection and it might benefit for dementia. 
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